144: Why Creatine Is One of the Most Important Brain Nutrients

Ben Bikman synthesizes a wide range of human clinical trials. He emphasizes that the brain relies on phosphocreatine as an emergency energy reserve, and that supplementation works best when the system is under strain—sleep loss, aging, vegan diet, depression, or injury. He details successful studies: 5 g/day for 6 weeks in vegetarians improving memory and fluid intelligence; 20 g/day for 1 week in elderly boosting multiple memory tasks; single-dose 0.35 g/kg protecting cognition during 21-hour sleep deprivation; 5-6 g/day adjunct in depression accelerating response and raising remission rates; and 0.5 g/kg in pediatric TBI reducing symptoms. He notes that women consistently respond more due to lower baseline reserves and estrogen's influence. His practical takeaway: creatine monohydrate is safe, cheap, and backed by RCTs, making it a valuable cognitive hygiene tool.

Ben Bikman explains that the brain, despite being only 2% of body mass, uses 20% of resting energy. ATP cannot be stored so cells need a milliseconds-fast backup, which the creatine-phosphocreatine system provides. Creatine kinase phosphorylates creatine into phosphocreatine, and when ATP is used, phosphocreatine donates its phosphate to ADP to regenerate ATP instantly. This system is positioned throughout neurons, including at synaptic vesicles, indicating creatine helps with neurotransmitter release and may act as a neuromodulator. This dual role—energy buffer and signaling support—makes creatine indispensable for cognition and mood regulation.

Bikman cites a 2024 study where a single high-dose creatine dose given during sleep deprivation sustained brain phosphocreatine and ATP levels, with cognitive benefits lasting up to 9 hours. He explains that under high neural energy demand, the creatine transporter temporarily accepts more exogenous creatine than normal, essentially 'opening the doors more readily.' This demand-driven mechanism is a paradigm shift because it suggests that timing creatine around periods of anticipated stress (e.g., shift work, sleep loss) could maximize neuroprotection.

The 2024 trial measured brain chemistry directly with phosphorus tracking and cognitive tests. Participants receiving creatine maintained normal phosphocreatine and ATP even when severely sleep-deprived, while the placebo group declined. The protective effect was most evident on prefrontal cortex-dependent tasks like working memory and executive control—the same functions that fail first with sleep loss. This suggests a strategic use: taking creatine before an anticipated all-nighter or prolonged wakefulness could buffer cognitive performance.

Bikman cites meta-analytic evidence that cognitive benefits are more pronounced in women, and the strongest antidepressant trials with creatine were conducted exclusively in women. He explains that women have lower muscle creatine stores, implying lower brain stores, and that estrogen influences creatine kinase activity and transporter expression. This convergence of evidence suggests that women, especially older or those on plant-based diets, are a priority population for creatine's brain benefits. The depression remissions rates in women adding creatine to SSRIs were faster and higher.

Bikman details the landmark trial in women on SSRIs: 5 g/day creatine led to significant improvements by week 2 versus week 4+ for placebo, and a separate adolescent trial found even SSRI-resistant depression improved with creatine, confirmed by increased prefrontal phosphocreatine on scans. A bipolar depression study showed 53% remission with creatine vs. 11% placebo, though two patients experienced hypomania, warranting caution. A 2025 systematic review confirms creatine significantly reduces depressive symptoms when combined with established treatments. The overarching hypothesis is that depression is partly a neuroenergetic insufficiency, and creatine restores cellular energy reserves.

Bikman describes two randomized studies in pediatric TBI where creatine at ~0.5 g/kg per day for 6 months reduced duration of post-traumatic amnesia, ICU stay, and disabling symptoms. The rationale: TBI triggers an immediate spike in energy demand while blood flow and mitochondrial function drop, so a topped-up phosphocreatine reserve could blunt the crisis. Preemptive supplementation in contact sports or combat scenarios is now under investigation, akin to a neuroprotective buffer. This is especially relevant given the lack of pharmaceutical options for concussion.